1920x700px Header selection v2 16 - Gordon Duncan

Our Team

Gordon Duncan

Gordon Duncan

Gordon Duncan, Angus Horner & William Cooper supported by U+I PLC are the Harwell Science & Innovation Campus private sector joint venture partners focused on accelerating the commercial development of the 710 acre Harwell Campus.
Gordon has spent much of his career involved in funding science. He started his career in investment banking with Deutsche Bank (Morgan Grenfell). He subsequently joined the Board of Kleinwort Benson and increasingly specialised in advising major multi-nationals in the life sciences sector on complex multi-$billion mergers as well as advising and investing in emerging pharmaceutical companies.

Gordon was closely involved with the London Stock Exchange in creating the rules to enable substantial scientific research based companies without an adequate trading record to raise finance by listing their securities and he has been involved in raising over $1billion for emerging pre-revenue companies. While Head of Healthcare at Dresdner Kleinwort Benson, the Bank held a dominant position in raising money for listed biotechs, for almost a decade. Gordon was later invited by the former chairman of SmithKline Beecham to join DLJ (now Credit Suisse) as Head of healthcare investment banking in Europe with a private equity focus.

Life Sciences / HealthTec represents ~25% of total UK R&D spend and is the UK’s most important R&D sector in terms of investment. The development of a strong Life Sciences / HealthTec Cluster at Harwell is a key focus.
Gordon qualified as a chartered accountant with PWC having graduated from Bristol University (BSc. Economics & Accounting). Gordon holds his FCA registration through STJ Advisors, a leading independent Equity Capital Markets advisor. He continues to advise healthcare companies on capital markets, M&A and licensing transactions, often alongside leading industry figures.
From 2011, Angus Horner and Gordon Duncan were partners in a consortium that secured exclusivity to acquire Pfizer’s 3 million sq.ft. R&D campus at Sandwich in Kent.

Other interests: Skiing (first descents in remote locations), Flying, Cycling, Scottish Art.